PIM1 and Miyoshi myopathy: Combination treatment with either of the c-Myc inhibitors enhanced killing by the Pim inhibitor SGI-1776 in both TRAF3−/− mouse primary B cells (Fig. 6a,b) and in the TRAF3-deficient human MM cell line RPMI8226 (Fig. 6c,d).